ImmunityBio’s Record Revenue Overshadowed by FDA Fallout and Cash Burn

ImmunityBio is posting its strongest-ever quarterly sales, yet the stock is heading in the opposite direction. The biotech group generated roughly $44.2 million in preliminary product revenue for the first quarter of 2026, a 168% surge from a year earlier and a 15% sequential improvement. The growth is being driven by its cancer drug Anktiva, which has now secured regulatory approvals in approximately 34 countries and recently began commercial sales in Saudi Arabia for bladder and lung cancer indications.

Despite those headline numbers, shares lost more than 8% last Friday and have been on a volatile ride. The stock opened the week at $8.22 before sliding as disappointing clinical data from a Phase 2 glioblastoma study triggered a 12% selloff. The broader overhang stems from a class-action lawsuit filed by shareholders who allege management overstated Anktiva’s efficacy. The litigation was sparked by an FDA warning letter issued in late March after founder Patrick Soon-Shiong claimed in a January podcast that the drug could treat all forms of cancer.

Court documents suggest the regulator had flagged concerns earlier, intensifying scrutiny on the company’s disclosures. The deadline for lead plaintiff designation is May 26, 2026, and multiple law firms are still recruiting claimants. The FDA letter alone wiped out nearly $2 billion in market capitalization when it was made public.

Should investors sell immediately? Or is it worth buying ImmunityBio?

Wall Street analysts remain broadly constructive. Seven analysts cover the stock, with a consensus buy rating and an average price target of $12.57. BTIG has argued that the FDA’s correspondence does not alter the fundamental commercial outlook. The company’s gross margin stands above 99%, but high operating expenses tied to research and development are consuming those gains entirely.

Cash burn remains a pressing concern. Free cash flow came in at negative $71.7 million in the latest period, though ImmunityBio still holds roughly $381 million in cash. To shore up its balance sheet, management drew down $75 million from an existing facility and converted debt into 4.6 million new shares. The company’s market valuation of $5.27 billion equates to roughly 73 times annual revenue, leaving little room for operational missteps.

On the clinical front, the pivotal QUILT-2.005 study has completed enrollment ahead of schedule. ImmunityBio expects to wrap up the trial in the second quarter of 2026 and plans to file a supplemental approval application for Anktiva by year-end. The full quarterly report is due in the coming weeks, and investors will be looking for concrete details on the legal defense strategy as the May deadline approaches.